The 'cytokine storm': molecular mechanisms and therapeutic prospects

R Karki, TD Kanneganti - Trends in immunology, 2021 - cell.com
Cytokine storm syndrome (CSS) has generally been described as a collection of clinical
manifestations resulting from an overactivated immune system. Cytokine storms (CSs) are …

Immune-mediated inflammatory disease therapeutics: past, present and future

IB McInnes, EM Gravallese - Nature Reviews Immunology, 2021 - nature.com
Immune-mediated inflammatory diseases are common and clinically diverse. Although they
are currently incurable, the therapeutic armamentarium for immune-mediated inflammatory …

Overview of the IL‐1 family in innate inflammation and acquired immunity

CA Dinarello - Immunological reviews, 2018 - Wiley Online Library
Summary The interleukin‐1 (IL‐1) family of cytokines and receptors is unique in immunology
because the IL‐1 family and Toll‐like receptor (TLR) families share similar functions. More …

Strategies toward rheumatoid arthritis therapy; the old and the new

M Abbasi, MJ Mousavi, S Jamalzehi… - Journal of cellular …, 2019 - Wiley Online Library
Currently, medications used to treat rheumatoid arthritis (RA) are glucocorticoids (GCs) and
nonsteroidal anti‐inflammatory drugs (NSAIDs), predominantly used for controlling the pain …

Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders

DD Arnold, A Yalamanoglu, O Boyman - Frontiers in immunology, 2022 - frontiersin.org
Background The cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated
disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be …

Caspase functions in cell death and disease

DR McIlwain, T Berger, TW Mak - Cold Spring Harbor …, 2013 - cshperspectives.cshlp.org
Caspases are a family of endoproteases that provide critical links in cell regulatory networks
controlling inflammation and cell death. The activation of these enzymes is tightly controlled …

Anakinra therapy for non-cancer inflammatory diseases

G Cavalli, CA Dinarello - Frontiers in pharmacology, 2018 - frontiersin.org
Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-
1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory …

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

CA Dinarello, A Simon… - Nature reviews Drug …, 2012 - nature.com
Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …

NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis

C Guo, R Fu, S Wang, Y Huang, X Li… - Clinical & …, 2018 - academic.oup.com
Nucleotide-binding, oligomerization domain (NOD)-like receptor family, pyrin domain
containing 3 (NLRP3) gene polymorphism was reported to be associated with susceptibility …

Treating inflammation by blocking interleukin-1 in humans

CA Dinarello, JWM van der Meer - Seminars in immunology, 2013 - Elsevier
IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific
IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …